Citations

Clear

13 citation(s) found for "Bendel, Emily".

Vascular Abnormalities in the Hand and Wrist: State-of-the-Art Multimodality Imaging
Bretzman, John P. , Bookwalter, Candice, Bendel, Emily , Rajiah, Prabhakar

Mayo Clinic

RadioGraphics | October 29, 2026 | Volume: 46 | Issue: 11 | Pages: No page available

10.1148/rg.250210 | PMID 42955840 Get It

A thorough understanding of hand and wrist vascular anatomy and disease patterns, combined with strategic use of multimodality imaging, enables radiologists to diagnose vascular diseases, guide clinical management, and help preserve limb function.
First-in-Human Safety and Feasibility of Nodal and Pedal MR Lymphangiography with Gadopiclenol
Thompson, Scott M. , Collins, Jeremy D. , Bendel, Emily C. , Reisenauer, Christopher J., Jundt, Michael C., Yalҫin, Müge, Favazza, Christopher , Lu, Aiming , McDonald, Robert J. , Williamson, Eric E. , Stinson, Eric G. , In, MyungHo, Favazza, Christopher P , Messina, Steven A , Collins, Jeremy , Williamson, Eric , Thompson, Scott , Bendel, Emily , In, Myung-Ho , Jundt, Michael C., In, Myung‐Ho , Messina, Steven A.

Mayo Clinic

Radiology: Cardiothoracic Imaging | July 2, 2026 | Volume: 8 | Issue: 4 | Pages: No page available

10.1148/ryct.260067 | PMID 42390347 Get It

Dynamic gadopiclenol-enhanced nodal and pedal MR lymphangiography was safe, with no adverse events, and feasible for imaging peripheral and central conducting lymphatic anatomy.
Foam sclerotherapy for symptomatic cysts in ADPKD, ADPLD and solitary cysts
Neidert, Newton B. , Kseibi, Firas, Martin, William P. , Bugazia, Seif, Bendel, Emily C. , Howe, Cassie, Helland, Ryan, Gregory, Adriana , Liestikow, Kathleen, Kline, Timothy L. , Vaughan, Lisa E. , Hogan, Marie C. , Neidert, Newton, Kline, Timothy, Hogan, Marie C , Torres, Vicente E.

Mayo Clinic

Nephrology Dialysis Transplantation | June 26, 2025 | Volume: 40 | Issue: 11 | Pages: 2169-2181

10.1093/ndt/gfaf111 | PMID 40586687 Get It

ABSTRACT Background This medical center migrated from alcohol to sotradecol foam sclerotherapy (SFS) because of perceived improved efficacy in managing symptomatic kidney and liver cysts. We report technical aspects, change in short- and long-term cyst volumes, patient-reported outcomes, safety and applications of the technique. Methods In this retrospective observational study, cases from January 2017 to December 2021 had TKCV/TLCV (per Targeted Kidney or Liver or Cyst analysis) segmented using a deep-learning algorithm and cyst segmentation software (pre-, post-procedure and longitudinally). TKCV/TLCV % change were evaluated using the one-sample Wilcoxon signed rank test. For analyses involving changes in cyst volumes, the median % change in cyst volume per patient was assessed. Longitudinal changes in cyst volumes were assessed using linear mixed models. Changes in quality of life (QOL) [Linear Analog Self-Assessment (LASA), Polycystic Liver Disease Quality of life Questionnaire (PLD-Q) and 12-item short-form (SF12)] were also assessed. Results There were 102 SFS sessions (38 kidney, 58 liver, 6 combined liver/kidney cysts) performed on 77 unique individuals included for analysis. Median [interquartile range (IQR)] % reductions in TKCV were –92.0% (IQR –98.2%, –82.7%, P < .001) and for TLCV were –83.1% (IQR –93.5%, –52.9%, P < .001). Among patients with multiple kidney procedures (n = 7), median % reduction in TKCV was –94.3% (IQR –96.6%, –92.4%, P = .023). For patients with multiple liver procedures (n = 11), median % reduction in TLCV was –63.3% (IQR –85.2%, –28.3%, P = .004). Results were similar among the four patients undergoing multi-stage procedures (n = 1 kidney, n = 3 liver). When measured longitudinally, both liver and kidney cyst volumes declined to levels near 0 mL by 1 year follow-up and remained stable several years later. LASA physical domain and PLD-Q QOL scores improved post-SFS procedure. Conclusion SFS led to substantial long-term reductions in TKCV/TLCV and improved QOL. SFS can augment cyst volume reduction in addition to tolvaptan (kidney cysts) and octreotide (liver cysts). In some individuals with large symptomatic cysts, multiple SFS procedures were safe and effective in reducing TLCV/TKCV and improving symptoms.
Primary Ovarian Non‐Gestational Placental Site Trophoblastic Tumor in a Pediatric Patient: A Case Report and Review of the Literature
McChesney, Marissa K., Hull, Nathan C. , Bendel, Emily C. , Ishitani, Michael B., Shahi, Maryam , Demirel, Nadir , Allen‐Rhoades, Wendy , Allen-Rhoades, Wendy A

Mayo Clinic

Pediatric Blood & Cancer | March 22, 2025 | Volume: 72 | Issue: 6 | Pages: No page available

10.1002/pbc.31671 | PMID 40119593 Get It

The Effects of Alfapump on Ascites Control and Quality of Life in Patients With Cirrhosis and Recurrent or Refractory Ascites
Wong, Florence , Vagas, Hugo E., Reddy, K. Rajender , Pagadala, Mangesh, Pocha, Christine , Bajaj, Jasmohan S. , Shlomovitz, Eran , Bendel, Emily C. , Capel, Jeroen , Kamath, Patrick S. , Group, The POSEIDON Study, Bajaj, Jasmohan S , Shlomovitz, Eran , Bendel, Emily , Capel, Jeroen , Kamath, Patrick S , Wong, Florence , Sundaram, Vinay , Group, The POSEIDON Study

Mayo Clinic

American Journal of Gastroenterology | January 6, 2025 | Volume: 120 | Issue: 10 | Pages: 2291-2301

10.14309/ajg.0000000000003300 | PMID 39760647 Get It

INTRODUCTION: The alfapump system has been shown to be a possible alternative to repeat therapeutic paracentesis (TP) in selected patients with refractory ascites (RA). The objective of this study was to assess the safety and efficacy of alfapump on ascites control and quality of life in these patients. METHODS: Patients with cirrhosis and RA requiring ≥2 TPs 30 days prior were enrolled and followed for 24 months postimplant. Primary efficacy end point assessed at 6 months was reduction in paracentesis requirement; safety end point was device-related adverse events resulting in intervention, explant, or death. RESULTS: Forty patients with RA (mean Model of End-stage Liver Disease-Sodium: 15 ± 4) received an alfapump. TP requirement was decreased from 3.2 ± 1.5 sessions per month preimplant to 0.2 ± 0.6 sessions per month at 6 months postimplant ( P < 0.001), with 77% of patients having ≥50% reduction. Six pumps (15%) were explanted within 6 months due to device-related adverse events, 3 (7.5%) due to pump site skin erosion, and 3 (7.5%) due to bladder discomfort. Twenty-four renal events occurred in the 0–6 month postimplant period; 16 cases were readily reversible stage 1 acute kidney injury. Ascites-related symptoms assessed with an Ascites Q score improved from 51.0 ± 19.3 preimplant to 32.2 ± 21.9 at 6 months postimplant ( P < 0.001). Physical but not mental components of Short Form 36 improved ( P < 0.001). The 5 deaths within 6 months postimplant were not directly related to the device or alfapump therapy. DISCUSSION: The alfapump system effectively controlled ascites, which improved quality of life. It may be considered as an alternative to repeat TP in select patients with RA. Complication rates were similar to those expected in patients with RA.
Paradoxical embolic stroke during catheter-directed thrombolytics in a patient with massive pulmonary embolism: A case report
Bendel, Emily C. , Ghorbanzadeh, Atefeh , Houghton, Damon E.

Mayo Clinic

Brain Circulation | July 15, 2024 | Volume: 11 | Issue: 1 | Pages: 86-88

10.4103/bc.bc_115_23 | PMID 40224554 Get It

Abstract: Paradoxical embolism represents a critical and potentially fatal complication that can be associated with pulmonary embolism (PE). This case details a unique case of massive PE, further complicated by embolic stroke occurring during catheter-directed thrombolytic therapy. There was no evidence of thrombosis during the initial evaluation with lower extremity Doppler ultrasound, abdominal computed tomography scan, and transthoracic echocardiography. Differentials for the source of the emboli include unrecognized left atrial appendage thrombus, pulmonary arteriovenous malformations, and a patent left foramen ovale. Our findings highlight the complexities and treatment challenges of massive PE.
Adjunctive Mesenchymal Stem Infusion Boosts Recovery of GFR After Renal Revascularization for Atherosclerotic Renovascular Disease
Abumoawad, Abdelrhman , Ferguson, Christopher M. , Bendel, Emily C. , Lerman, Lilach O. , Textor, Stephen C., Saad, Ahmed , Eirin, Alfonso , Herrmann, Sandra M. , Hickson, LaTonya J.

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 31 | Issue: 10S | Pages: 645-645

10.1681/asn.20203110s1645b Get It

Prospective Observational Study of Pain Severity and Pain Interference Outcomes Following Percutaneous MRI-guided Laser Ablation or Cryoablation for Focal Painful Peripheral, Soft Tissue Vascular Malformations: 12-month Outcomes
Koepsel, Erica M. Knavel , Powell, Garret M. , Bendel, Emily C. , Howe-Clayton, Desirae L., Favazza, Christopher , Lu, Aiming , Anderson, Katelyn , Tollefson, Megha M. , Woodrum, David A. , Thompson, Scott M. , Bjarnason, Haraldur , Polites, Stephanie F. , Adamo, Daniel A.

Mayo Clinic

Journal of Vascular Anomalies | January 4, 2023 | Volume: 4 | Issue: 1 | Pages: e055

10.1097/jova.0000000000000055 Get It

Background: Percutaneous image-guided thermal ablation has emerged as a treatment option for vascular malformations (VM). However, prospective data on intermediate to long-term effectiveness with uniform follow-up are lacking. Purpose: To prospectively evaluate the 12-month pain severity and pain interference outcomes following percutaneous MRI-guided laser ablation and cryoablation of focal painful, peripheral soft tissue VM. Materials and Methods: Participants undergoing clinically indicated MRI-guided laser ablation and cryoablation for focal painful (worst pain ≥4 out of 10 on Visual Analog Scale), peripheral soft tissue vascular malformations (VM) were enrolled in an IRB-approved prospective, observational study after giving informed consent. Participants completed the Brief Pain Inventory questionnaire prior to ablation and 1, 3, 6, and 12-month postablation. Differences in pain severity and interference outcomes from baseline on a 0 to 10 scale were compared using a paired t-test. Results: Seventeen participants (15 female; mean age 28.3 ± 9.3 years) underwent 24 MRI-guided and monitored ablation sessions including laser (n = 21), cryoablation (n = 2), or both (n = 1) for treatment of painful slow-flow (n = 16) or high-flow (n = 1) VM. Median maximal VM diameter was 5.7 cm (range 1.1 to 31.0 cm). Mean (±SD) preablation worst pain score was 7.9 ± 1.4. There was a significant decrease in worst pain at 1-month postablation (–3.5 ± 2.9; P = .0007) that was sustained at 3 (–3.4 ± 3.2; P = .0007), 6 (–4.2 ± 3.6; P = .0003), and 12 months (–3.6 ± 3.9; P = .002), with similar results for average, current, and least pain scores. There was a significant improvement in pain interference outcomes at 12-month postablation: general activity (P = .018), walking ability (P = .008), work (P = .003), sleep (P = .007), and enjoyment of life (P = .033). Conclusions: These data suggest that MRI-guided and monitored thermal ablation is safe and provides early and sustained significant improvements in pain severity and pain interference outcomes during the first year of follow-up in participants with focal painful peripheral soft tissue VM.
Endoscopic Ultrasound–Guided Dual Ultrasound Hepatic Cyst Aspiration and Sclerotherapy to Ameliorate Portal Hypertension
Levy, Michael J. , Bendel, Emily C. , Reisenauer, Christopher J., Codipilly, Don C. , Dean, Patrick G. , Gleeson, Ferga C., Kalra, Manju , Prieto, Mikel , Taner, Timuçin , Kamath, Patrick S. , Bjarnason, Haraldur , Levy, Michael J. , Amer, Hatem , Gleeson, Ferga C. , Heimbach, Julie K. , Stegall, Mark D.

Mayo Clinic

American Journal of Gastroenterology | February 17, 2022 | Volume: 117 | Issue: 5 | Pages: 715-716

10.14309/ajg.0000000000001689 | PMID 35175966 Get It

MR-guided Cryoablation for the Treatment of Symptomatic Pedal Vascular Malformations
Koepsel, Erica M. Knavel , Bendel, Emily C. , Augustine, Matthew , Tollefson, Megha M. , Gorny, Krzysztof R. , Lu, Aiming , Favazza, Christopher , Woodrum, David A. , Thompson, Scott M.

Mayo Clinic

Journal of Vascular Anomalies | December 3, 2021 | Volume: 2 | Issue: 4 | Pages: e029

10.1097/jova.0000000000000029 Get It

Objective: Vascular malformations are benign vascular anomalies characterized by abnormally developed arterial, venous, and lymphatic structures, which are often symptomatic. Historical and current treatment techniques include intravascular embolization/sclerosis and surgical resection. While these techniques have proven to be successful at managing and treating these types of lesions, these techniques are not without risk, especially in the small spaces of the hands and feet. Cryoablation for the treatment of low-flow vascular malformations is a new and evolving technique. We present five cases of symptomatic pedal vascular malformations treated with MR guided cryoablation, which provides encouraging safety and feasibility results for these difficult to treat lesions. Methods: A retrospective review of patients who had undergone MR-guided cryoablation of their pedal vascular malformations between January 2016 and January 2020 was performed. Results: Five cryoablations were completed without immediate complication. All patients reported markedly decreased pain corresponding to the treated area and improvement in their ability to return to a more active lifestyle. Two patients experienced mild transient numbness which resolved by 2–3 months and one patient experienced a transient motor and sensory neuropathy which resolved by 6 months. Conclusion: We present five cases of successful MR-guided cryoablation of symptomatic pedal venous malformations. Many of the patients included in this review failed conservative and other interventional/surgical treatments. The treatment options for this patient cohort can be limited given small space within the plantar aspect of the foot. Cryoablation of these lesions can be performed safely especially under continuous MRI monitoring. Level of Evidence: Case series (Level 4)